RETEVMO

This brand name is authorized in United States. It is also authorized in Israel, Japan.

Active ingredients

The drug RETEVMO contains one active pharmaceutical ingredient (API):

1	Selpercatinib UNII CEGM9YBNGD - SELPERCATINIB
	Selpercatinib is an inhibitor of the rearranged during transfection (RET) receptor tyrosine kinase. Selpercatinib inhibited wild-type RET and multiple mutated RET isoforms as well as VEGFR1 and VEGFR3 with IC50 values ranging from 0.92 nM to 67.8 nM. In in vitro and in vivo tumor models, selpercatinib demonstrated anti-tumor activity in cells harboring constitutive activation of RET protein resulting from gene fusions and mutations, including CCDC6-RET, KIF5B-RET, RET V804M, and RET M918T.
	Read more about Selpercatinib

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
RETEVMO Capsule	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01EX22		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01E Protein kinase inhibitors → L01EX Other protein kinase inhibitors
Discover more medicines within L01EX22

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
IL	מִשְׂרַד הַבְּרִיאוּת	9243, 9244
JP	医薬品医療機器総合機構	4291075M1027, 4291075M2023
US	FDA, National Drug Code	0002-2980, 0002-3977